Acute ischaemic stroke patients with active cancer had a higher 1-year risk of death (aHR 1.91; 95% CI 1.50-2.43) and cerebrovascular recurrence compared to non-cancer patients.
Cohort (n=5,986)
No
Does active cancer worsen clinical outcomes, mortality, and recurrence in patients with acute ischaemic stroke compared to non-cancer patients?
Active cancer in acute ischemic stroke patients is associated with a significantly higher 1-year risk of death and cerebrovascular recurrence compared to non-cancer patients, despite having fewer traditional vascular risk factors.
Effect estimate: aHR 1.91 (95% CI 1.50-2.43)
BACKGROUND AND PURPOSE: Demographics, clinical characteristics, stroke mechanisms and long-term outcomes were compared between acute ischaemic stroke (AIS) patients with active cancer (AC) versus non-cancer patients. METHODS: Using data from 2003 to 2021 in the Acute STroke Registry and Analysis of Lausanne, a retrospective cohort study was performed comparing patients with AC, including previously known and newly diagnosed cancers, with non-cancer patients. Patients with inactive cancer were excluded. Outcomes were the modified Rankin Scale (mRS) score at 3 months, death and cerebrovascular recurrences at 12 months before and after propensity score matching. RESULTS: Amongst 6686 patients with AIS, 1065 (15.9%) had a history of cancer. After excluding 700 (10.4%) patients with inactive cancer, there were 365 (5.5%) patients with AC and 5621 (84%) non-cancer AIS patients. Amongst AC patients, 154 (42.2%) strokes were classified as cancer related. In multivariable analysis, patients with AC were older (adjusted odds ratio aOR 1.02, 95% confidence interval CI 1.00-1.03), had fewer vascular risk factors and were 48% less likely to receive reperfusion therapies (aOR 0.52, 95% CI 0.35-0.76). Three-month mRS scores were not different in AC patients (aOR 2.18, 95% CI 0.96-5.00). At 12 months, death (adjusted hazard ratio 1.91, 95% CI 1.50-2.43) and risk of cerebrovascular recurrence (sub-distribution hazard ratio 1.68, 95% CI 1.22-2.31) before and after propensity score matching were higher in AC patients. CONCLUSIONS: In a large institutional registry spanning nearly two decades, AIS patients with AC had less past cerebrovascular disease but a higher 1-year risk of subsequent death and cerebrovascular recurrence compared to non-cancer patients. Antithrombotic medications at discharge may reduce this risk in AC patients.
Costamagna et al. (Thu,) conducted a cohort in Acute ischaemic stroke (AIS) (n=5,986). Active cancer vs. Non-cancer was evaluated on Death at 12 months (aHR 1.91, 95% CI 1.50-2.43). Acute ischaemic stroke patients with active cancer had a higher 1-year risk of death (aHR 1.91; 95% CI 1.50-2.43) and cerebrovascular recurrence compared to non-cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: